Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples